Lantheus Holdings Inc Dossier
|
SectorHealth Care IndustryDrug Manufacturers - Specialty & Generic Beta (adjusted)0.31 Intrinsic Value $101.30median of 6 methods · middle span $74-$240based on filings through 30 Jun 2026 Market Price $99.65Price as of 1 Oct 2026 Near fair valueIntrinsic value is 2% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $6.5B Enterprise Value $6.5B Shares Outstanding 63.9M diluted Moat Rating Wide Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Lantheus Holdings is transitioning from a diagnostics-focused business to a high-margin, diversified radiopharmaceutical leader. Despite competitive pricing pressures on its flagship prostate cancer imaging agent, PYLARIFY, the company's core portfolio (including DEFINITY and the rapidly growing Alzheimer's imaging agent Neuraceq) remains highly resilient. The recent FDA approval of PYLARIFY TruVu and tentative approval of PNT2003 position the company for accelerated growth starting in 2027. Furthermore, the active $7 billion takeover proposal from Curium provides a strong valuation floor and highlights the strategic value of Lantheus's end-to-end radiopharmaceutical manufacturing and distribution network. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$102.50 Mean target$107.04 High · most bullish analyst$115.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $80.0020% Takeover discussions with Curium fall through, and intensifying competition in the PSMA PET market leads to steeper-than-expected pricing erosion for PYLARIFY, offsetting growth in the neurology and cardiology segments. Base CaseCentral scenario $107.0450% Matches the consensus meanLantheus continues to execute its disciplined commercial strategy, maintaining its dominant position in PSMA PET and ultrasound-enhancing agents. The company achieves its FY2026 guidance of $1.4 billion to $1.45 billion in revenue and adjusted EPS of $5.00 to $5.25, while successfully transitioning to a permanent CEO. Bull CaseUpside scenario $115.0030% Curium successfully acquires Lantheus at a premium (valuing the company at $7 billion or more), or Lantheus accelerates its market share recapture in 2027 through a highly successful rollout of PYLARIFY TruVu and the commercial launch of PNT2003 following the resolution of the Hatch-Waxman stay. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |